This company has shut down. SalioGen Therapeutics is no longer operating — its last tracked round was a Series B in 2022.
Explore the Startup GraveyardSalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders.
SalioGen Therapeutics has raised $115.0M in total funding. The most recent round was Series B. The last funding was announced in January 2022.
SalioGen Therapeutics's investors include Fidelity, T. Rowe Price, D1 Capital Partners, Cystic Fibrosis Foundation, EPIQ Capital Group.
SalioGen Therapeutics is headquartered in Burlington, United States.
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders.
SalioGen Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"SalioGen Therapeutics — Funding & Investors." VCBacked, January 5, 2022, https://www.vcbacked.co/company/saliogen-therapeutics. Accessed September 6, 2026.
VCBacked. (2022). SalioGen Therapeutics — Funding & Investors. Retrieved September 6, 2026, from https://www.vcbacked.co/company/saliogen-therapeutics
{{cite web |title=SalioGen Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/saliogen-therapeutics |website=VCBacked |access-date=September 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated